Rotavirus infections vaccine - Hilleman Laboratories

Drug Profile

Rotavirus infections vaccine - Hilleman Laboratories

Alternative Names: HSRV; Pentavalent heat-stable rotavirus vaccine

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MSD Wellcome Trust Hilleman Laboratories
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Rotavirus infections

Most Recent Events

  • 01 Apr 2017 MSD Wellcome Trust Hilleman Laboratories and Parexel completes a phase I/II trial in Rotavirus infections (Prevention, In infants, In adults, In children, In adolescents) in Bangladesh (PO) (NCT02728869)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top